IL17A and metabolic syndrome: When comparing inflammatory alterations observed in patients with clinical manifestations of the metabolic syndrome to those that selectively improved in responding patients, the parameters determining lack of treatment response in this patient group may be percentage of intermediate monocytes, IL-17 and IgG levels.